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Available online 21 February 2017Objectives: This 109-week, nonrandomized, observational study of mucopolysaccharidosis II (MPS II) patients al-
ready enrolled in the Hunter Outcome Survey (HOS) (NCT00882921), assessed the long-term immunogenicity of
idursulfase, and examined the effect of idursulfase-specific antibody generation on treatment safety (via infu-
sion-related adverse events [IRAEs]) and pharmacodynamics (via urinary glycosaminoglycans [uGAGs]).
Methods:Male patients ≥5 years, enrolled in HOS regardless of idursulfase treatment status were eligible. Blood/
urine samples for anti-idursulfase antibody testing and uGAG measurement were collected every 12 weeks.
Results: Due to difficulties in enrolling treatment-naïve patients, data collection was limited to 26 enrolled pa-
tients of 100 planned patients (aged 5.1–35.5 years) all of whomwere non-naïve to treatment. Fifteen (58%) pa-
tients completed the study. There were 11/26 (42%) seropositive patients at baseline (Ab+), and 2/26 (8%)
others developed intermittent seropositivity by Week 13. A total of 9/26 patients (35%) had ≥1 sample positive
for neutralizing antibodies. Baseline uGAG levelswere low due to prior idursulfase treatment and did not change
appreciably thereafter. Ab+patients had persistently higher uGAG levels at entry and throughout the study than
Ab− patients. Nine of 26 (34%) patients reported IRAEs. Ab+ patients appeared to have a higher risk of devel-
oping IRAEs thanAb− patients. However, the relative riskwas not statistically significant and decreased after ad-
justment for age.
Conclusions: 50% of study patients developed idursulfase antibodies. Notably Ab+ patients had persistently
higher average uGAG levels. A clear association between IRAEs and antibodies was not established., Hospital de Cl
-003, Brazil.
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Hunter syndrome (mucopolysaccharidosis II [MPS II]) is character-
ized by a deficiency in iduronate-2-sulfatase, a key enzyme in the catab-
olism of glycosaminoglycans (GAGs) [1]. Individuals display significantinicas de Porto
il.cho.org
hildrensmn.org
iu),
ijayaraghavan),
.
access article undermorbidity and early mortality, with approximately two-thirds
experiencing progressive cognitive impairment (severe phenotype)
and approximately one-third of patients demonstrating intact cognition
(attenuated phenotype) [2].
Recombinant iduronate-2-sulfatase (idursulfase, Elaprase®, Shire,
Lexington,MA, USA) is approved inmany countries for enzyme replace-
ment therapy (ERT) of patients with MPS II [3].
While studies of idursulfase have consistently demonstrated safety
and efficacy, roughly 50% of patients produce idursulfase-specific
serum immunoglobulin G (IgG) antibodies [3–5].
This 109-week, nonrandomized, observational study of Hunter syn-
drome patients was a sub-study within the Hunter Outcome Survey
(HOS), a global registry of patients with Hunter syndrome, establishedthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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monitor the long-term safety and effectiveness of idursulfase in a
large patient cohort [6]. The study monitored anti-idursulfase antibody
development in Hunter syndrome patients after long-term idursulfase
ERT and was designed to include patients in HOS who had previously
received idursulfase, as well as treatment-naïve HOS patients who had
planned to begin idursulfase treatment within 30 days of enrollment
in this study. The primary study objective was to evaluate the effect of
anti-idursulfase IgG, IgM, and IgE antibodies on idursulfase safety (as
measured by infusion-related adverse events [IRAEs]) between patients
who develop anti-idursulfase antibodies and patients who do not after
long-term idursulfase ERT (NCT00882921). The secondary study objec-
tive was to evaluate the effects of anti-idursulfase IgG antibodies on
idursulfase pharmacodynamics (as measured by urinary glycosamino-
glycan [uGAG] levels).
2. Methods
2.1. Patient selection
Inclusion criteriawere:male patients ≥5 years of age, and enrolled in
HOS (i.e., met the entry criteria of a documented diagnosis of Hunter
syndrome); receiving idursulfase treatment or scheduled to begin
idursulfase treatment within 30 days of study enrollment; and with
signed IRB/IEC-approved informed consent. Patients were not enrolled
if they had received biologic or ERT products other than idursulfase or
other investigational products within 30 days prior to study entry, if
the patient had a life expectancy of b2 years, or if the patientwas unable
to comply with the protocol.
2.2. Study design
Baseline values were recorded up to 30 days prior to the first
idursulfase infusion in the study. The treatment period ran from Week
1 through Week 109 (approximately 2 years). Baseline and Week 1
study visits could occur on the same day provided that all selection
criteria were met.
Baseline data included: medical history, physical examination,
serum anti-idursulfase antibody levels (IgG, IgM, and IgE), and uGAG
levels and urine creatinine. Cognitive impairment (“yes/no”) was
assessed by the HOS investigator prior to or within 6 months after
study entry.
Vital signs and infusion rates (start and end time points) were re-
corded at each weekly infusion visit. Blood and urine samples were col-
lected every 3 months for anti-idursulfase antibody testing, and uGAG
and urine creatinine measurements.
Patients weremonitored for the occurrence of adverse events (AEs),
and the use of concomitant medications.
2.3. Antibodies
Positive samples from preliminary anti-idursulfase IgG screening
using the conformation-specific antibody (CSA) or isotype specific en-
zyme-linked immunosorbent assays (ELISA) [3] were confirmed by a
corresponding isotype-specific radioimmunoprecipitation (RIP) assay
[4]. Positive results of the RIP assay, were reported as positive and the
titer determined by either the CSA or ELISA. Negative RIP results were
reported as antibody negative. Overall antibody status referred to the
anti-idursulfase IgG antibody result, and was defined as positive if one
or more IgG results were found to be positive during the study.
All antibody-positive samples were analyzed for neutralizing anti-
bodies with both an in vitro activity neutralizing antibody assay and a
cell-based internalization antibody assay [7,8].
IgG antibody status was classified into the following categories for
each individual patient: 1) Antibodypositive (Ab+): A patientwas con-
sidered Ab+ if one or more IgG antibody results were positive duringthe course of study. 2) Antibody negative (Ab−): A patient was Ab−
if all the IgG antibody results were negative during the course of study.
For each individual patient, neutralizing antibody status was classi-
fied into one of two categories: 1) Overall neutralizing antibody status
positive (NAb+): A patient was considered NAb+ if one or more in
vitro enzyme activity inhibition assays or one or more cell-based-inter-
nalization assays were positive during the course of study. 2) Overall
neutralizing antibody status negative (NAb−): A patient was consid-
ered NAb− if all the in vitro enzyme activity inhibition assays and all
the cell-based-internalization assays were negative during the course
of study.
2.4. Safety and pharmacodynamics measurements
Urinary GAG levels, normalized to urinary creatinine concentration
(to control for variations in urine flow rate) were analyzed by a central
laboratory (Shire, Lexington, MA).
AEs, treatment-emergent AEs (TEAEs), serious AEs (SAEs), and
IRAEs were monitored. TEAEs were defined as all AEs occurring on or
after the date of first idursulfase infusion within the current study and
within 30 days of the patient's last infusion. IRAEs were defined as all
AEs that occurred during the infusion, or within 24 h following the infu-
sion; and were judged as possibly or probably related to idursulfase
infusion.
2.5. Data analyses
The change and percentage change from baseline in uGAG levels
were compared between antibody groups using the Wilcoxon rank
sum test. IRAE rates by antibody status groups (Ab+ versus Ab−)
were compared. For analysis, we conservatively assumed that any sero-
conversion occurring after study baseline and on or beforeWeek 13 oc-
curred by the date of first study infusion. To account for potentially
differing follow-up times between antibody groups, the analysis was
based on a negative binomial regression model. This model (model 1)
was used to estimate the rate of IRAEs and the relative risk comparing
positive with negative antibody status groups. Similarly, the above
model was used to assess the impact of neutralizing antibody status
on IRAE incidence. The negative binomial model (model 2) was used
to explore the impact of adjustment for age at study enrollment (classi-
fied as b12 years versus ≥12 years). Generally no imputation of missing
data was performed and all analyses were considered exploratory in
this observational cohort study.
3. Results
3.1. Study population
Due to difficulties identifying idursulfase ERT-naïve patients in this
rare disease population, the study was modified to halt enrollment
and complete the collection of data for the 26 non-naïve patients. No
treatment-naïve patients were included in the study.
The characteristics of the 26 patients at baseline are shown in
Table 1.
Eleven patients discontinued the study: due to investigator termina-
tion (3 out of 26), lost to follow-up (2/26), death (2/26), withdrawal of
consent (1/26), other reasons (3/26). The remaining 15 patients com-
pleted the study. Median duration of idursulfase ERT prior to study en-
rollment was 35.8 months, and all patients had received at least
6 months of treatment with idursulfase prior to entering the study.
The presence of cognitive impairment was assessed by the HOS investi-
gator for 24 of the 26 enrolled patients. Twelve of 16 patients (75%)who
were b12 years had cognitive impairment, whereas only 1 of 8 (12.5%)
patients ≥12 years did.
Eleven out of 26 patients were seropositive at study baseline and 2
additional patients became so between baseline and Week 13, or at
Table 1
Baseline characteristics by overall immune status.
Baseline
characteristics
Overall
(N = 26)
Ab+
(n = 13)
Ab−
(n = 13)
NAb+
(n = 9)
NAb−
(n = 17)
Age category, n (%)
b12 years 17 (65.4) 10 (76.9) 7 (53.8) 7 (77.8) 10 (58.8)
≥12 years 9 (34.6) 3 (23.1) 6 (46.2) 2 (22.2) 7 (41.2)
Age at entry, y
Mean (SD) 12.8 (8.0) 9.3 (2.9) 16.3 (9.9) 9.5 (3.1) 14.6 (9.3)
Median 10.0 9.4 11.2 9.4 10.1
Min, Max 5.1, 35.5 5.8, 14.5 5.1, 35.5 6.2, 14.5 5.1, 35.5
Age at diagnosis, y
Mean (SD) 4.4 (3.9) 3.5 (1.7) 5.3 (5.2) 3.3 (1.8) 5.0 (4.6)
Median 3.8 4.1 3.0 3.5 4.1
Min, Max 0.1, 20.0 0.1, 5.5 0.1, 20.0 0.1, 5.5 0.1, 20.0
Idursulfase ERT exposure before baseline, mo
Mean (SD) 39.9 (21.5) 32.9
(17.9)
47.0
(23.0)
36.6
(19.8)
41.7 (22.7)
Median 35.8 29.1 42.6 29.5 35.9
Min, Max 6.2, 77.5 10.6, 75.7 6.2, 77.5 10.6, 75.7 6.2, 77.5
Presence of cognitive impairmenta, n (%)
Yes 13 (54.2)b 8 (61.5) 5 (38.5) 7 (53.8) 6 (46.2)
No 11 (45.8)b 4 (36.4) 7 (63.6) 2 (18.2) 9 (81.8)
All patients were on weekly 0.5 mg/kg intravenous idursulfase.
Overall antibody statuswas defined as positive if one ormore IgG resultswere found to be
positive during the study.
Ab+, antibody positive; Ab−, antibody negative; ERT, enzyme replacement therapy;
NAb+, neutralizing antibody positive; NAb−, neutralizing antibody negative.
a Assessed prior to or within 6 months after entry into study.
b N = 24.
4 R. Giugliani et al. / Molecular Genetics and Metabolism Reports 12 (2017) 2–7the Week 13 evaluation. As antibody testing was performed at discrete
time points (e.g. study baseline [up to 30 days prior to first infusion] and
Week 13), the exact time of any seroconversion is unknown. Baseline
data show the majority of patients b12 years were Ab+ (10/17, 59%),
and the majority of patients ≥12 years were Ab− (6/9, 67%). This was
also true for baseline neutralizing antibody status. Patients who were
Ab+ and NAb+ at baseline were diagnosed with MPS II at a younger
age (mean age at diagnosis 3.49 and 3.31 years, respectively) than
those who were Ab− and NAb− (5.34 and 5.00 years, respectively).
Median exposure to idursulfase at baseline was lower in the Ab+
group (29.1 months) than in the Ab− group (42.6 months).
No patients seroconverted (became Ab+) afterWeek 13, and only 2
patients tested positive for the first time at Week 13.Fig. 1. Mean normalized uGAG (μg/mg) by visit and IgG Ab status (A) and NAb status (B)
glycosaminoglycan.Eight of 13 patients (61.5%) who had cognitive impairment were
Ab+overall, whereas only 4 of 11 (36.4%) patientswithout impairment
were Ab+. Seven of 13 patients (53.9%)who had cognitive impairment
were NAb+ overall, whereas only 2 of 11 (18.2%) patients without cog-
nitive impairment were NAb+.
Four patients tested positive for idursulfase-specific IgM. None of the
patient samples in this study were positive for IgE.
3.2. Pharmacodynamics
3.2.1. uGAGs by Ab status
At baseline, patients in the Ab+ group had higher uGAG levels
(mean 386 ± 279 μg/mg [43.7 ± 31.6 mg/mmol creatinine]) than pa-
tients in the Ab− group (mean 138 ± 76 μg/mg [15.6 ± 8.6 mg/mmol
creatinine]) (Fig. 1 A).
Normal reference range for uGAG levels, adopted for this study, are
≤16.0 mg GAG/mmol creatinine in children aged 3–5 years, and
≤6.5 mg GAG/mmol creatinine in those aged N14 years [9]. Pretreat-
ment uGAG levels were not known because all patients in this study
were on idursulfase ERT at baseline. Therefore, no assessment could
be made regarding the role of antibodies on the pharmacodynamic re-
sponse to idursulfase, so whether the higher baseline uGAG levels ob-
served in Ab+ patients vs Ab− patients were due to differences in
therapeutic response cannot be determined. In general, uGAG levels
for both Ab+ and Ab− patients remained stable and none of the differ-
ences between Ab+ and Ab− patients in mean change and mean %
change from study baseline were statistically significant. Results for
NAb were similar to those for overall antibody status (Fig. 1 B).
3.3. Safety
AEs were experienced by 25/26 (96.2%) patients overall. These AEs
were generally mild to moderate (Table 2).
Sixteen patients experienced SAEs, including 2 patients who died
during the study. The most common SAEs were convulsion (5/26,
19.2%) followed by lower respiratory tract infection (3/26, 11.5%). Cen-
tral line infection, upper respiratory tract infection, carpal tunnel syn-
drome, psychiatric disorder and agitation were reported SAEs in 2
patients (7.7%) each. All of the events were considered by the investiga-
tor to be unrelated to idursulfase treatment, except for the one IRAE of
central line infection. In general, Ab+ and NAb+ patients experienced
more SAEs (69.2% and 88.9%, respectively) than Ab− and NAb− pa-
tients (53.8% and 47.1%, respectively).. Ab, antibody; IgG, immunoglobulin G; NAb, neutralizing antibodies; uGAG, urinary
Table 2
Summary of TEAEs by IgG Ab status, and NAb status.
Description, n (%) Antibody status
Overall Ab+ Ab− NAb+ NAb−
(N = 26) (n = 13) (n = 13) (n = 9) (n = 17)
No AE 1 (3.8) 1 (7.7) 0 1 (11.1) 0
Any AE 25 (96.2) 12 (92.3) 13 (100.0) 8 (88.9) 17 (100.0)
Deaths 2 (7.7) 2 (15.4) 0 2 (22.2) 0
Discontinued due to an AE 2 (7.7) 2 (15.4) 0 2 (22.2) 0
Adverse drug reaction 9 (34.6) 5 (38.5) 4 (30.8) 4 (44.4) 5 (29.4)
SAE 16 (61.5) 9 (69.2) 7 (53.8) 8 (88.9) 8 (47.1)
Severe or
life-threatening AE
12 (46.2) 7 (53.8) 5 (38.5) 7 (77.8) 5 (29.4)
IRAE 9 (34.6) 5 (38.5) 4 (30.8) 4 (44.4) 5 (29.4)
Ab, antibody; Ab+, antibody positive; Ab−, antibody negative; AE, adverse event; IRAE,
infusion-related adverse event; NAb+, neutralizing antibody positive; NAb−, neutraliz-
ing antibody negative; SAE, serious adverse event; TEAE, treatment-emergent adverse
event.
Table 3
Comparing IRAE rates between Ab+ and Ab−, NAb+ and NAb −: negative binomial
regression model.
Model Independent variable Estimated
IRAE rate
RR 95% CI P-value
Ab±
1 IgG antibody status 2.873 0.731, 11.296 0.1309
Ab+ 0.0121
Ab− 0.0042
2 IgG antibody status 2.082 0.563, 7.706 0.2718
Ab+ 0.0055
Ab− 0.0026
Age at study entry 6.79 0.766, 60.225 0.0854
b12 Years 0.0099
≥12 Years 0.0015
NAb±
1 IgG antibody status 2.976 0.788, 11.239 0.1078
NAb+ 0.0148
NAb− 0.0050
2 IgG antibody status 2.264 0.661, 7.755 0.1934
NAb+ 0.0066
NAb− 0.0029
Age at study entry 6.848 0.782, 59.932 0.0822
b12 Years 0.0114
≥12 Years 0.0017
The IRAE average weekly rates, RR with 95% CI and P-value are based on the negative bi-
nomial model. The dependent variable is the count of the number of IRAEs, and the offset
variable is the natural log of the time in weeks from first study infusion to last on-study
assessment (Week 109 or early termination).
Ab+, antibody positive; Ab−, antibody negative; IRAE, infusion-related adverse event;
NAb+, neutralizing antibody positive, NAb−, neutralizing antibody negative; RR, relative
risk.
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died during the study (one from pneumonia and one from respiratory
failure), likely due to progression of the underlying disease. The most
common AEs overall were pyrexia (14/26 patients, 54%), followed by
upper respiratory tract infection (13/26, 50%), cough (11/26, 42%), ear
infection, lower respiratory tract infection, and fall (9/26, 35% each).
The AEswere generally similar in all antibody groups. Nine out of 26 pa-
tients overall (35%) experienced an adverse drug reaction, with adverse
drug reaction defined as any TEAE event considered to be related to the
study drug. Pyrexia was themost frequent adverse drug reaction (4/26,
15.4%) in all antibody groups.
At least one IRAEwas experienced by 9/26 (35%) of patients. The in-
terpretation of IRAE incidence is complicated by the fact that a total of
14/26 patients (including 7 patients atWeek 1) received premedication
to prevent IRAEs, and none of the patients enrolled in the study were
treatment naïve. The most common IRAEs overall were pyrexia (4/26,
15%) and headache (3/26, 12%). These were the only IRAEs reported
by 3 (≥10%) or more patients. In this small study dataset, Ab+ patients
appeared to have a higher risk of developing an IRAE than Ab− patients
(Table 3).
In comparing the Ab+ with the Ab− groups, Ab+ patients had an
almost 3-fold higher risk of an IRAE (with a Relative Risk [RR] = 2.87)
(model 1 in Table 3). Inclusion of age as a variable in the model de-
creased the RR estimate to 2.08 (model 2 in Table 3), showing that
age was an important confounder in the model.
The relationship between NAb status, age, and risk of an IRAE was
similar to that observed in the Ab groups, with the RR of an IRAE
being about 2-fold higher in the NAb+ group after adjusting for age.
However, no antibody or age group differences were statistically signif-
icant at the 5% level.
4. Discussion
Intravenous ERT with idursulfase is the standard treatment for pa-
tients with Hunter syndrome [10]. Several papers have described effica-
cy, safety, and antibody formation for idursulfase ERT in treatment-
naïve patients, both in young children (up to 7.5 years) [11,12], and pa-
tients 6 years and older [3–5].
This 2-year study assessed antibody status, pharmacodynamic effect
(uGAG levels) and safety, specifically infusion-related reactions in pa-
tients receiving long-term idursulfase. The main limitation to interpre-
tation of study results was the fact that the patients were not
treatment-naïve at study entry and therefore pre-ERT assessments
were not available. Other limitations were that for individual patients,
the risk for IRAEs wasmodified by the use of premedication prior to en-
rollment and small sample sizes limited the ability to detect statistical
differences. Premedication treatments included reduction in speed of
infusion, and administration of antihistamines or steroids. The studywas also relatively short, given that patients are generally receiving
long term treatment. A further limitation is that genotype data for this
patient population are not available for analysis.
Half of the patients (13/26) were seropositive at some point during
this 2 year study, and 11/13 of these were already seropositive at base-
line. The immunogenicity analysis of the original pivotal, phase 2/3
idursulfase study and 2-year extension phase similarly found 50% of pa-
tients had developed antibodies [3,5]. In the phase 2/3 study, neutraliz-
ing antibodies were found in about one-fifth of patients (13/63, 21%),
compared with 35% (9/26) found in the current study, possibly due to
differing geneticmake-up of the study populations [4]. Our data suggest
a relationship between cognitive impairment, age, and seropositivity.
Three fourths (75%) of younger patients (b12 years) were cognitively
impaired, whereas only 1 patient (12.5%) ≥12 years was cognitively im-
paired. Cognitively impaired patients were more likely to be Ab+ and
NAb+ (61.5% and 53.9%, respectively) compared with those who
were cognitively intact (36.4% and 18.2%, respectively). Ab− patients
tended to be older with greater prior ERT exposure. An explanation
for this may be that patients diagnosed earlier tend to havemore severe
disease and thismay reflect a genotype that is more predictive of severe
disease (such as complete deletion/large rearrangement, or nonsense
mutations versus more benign missense mutations) [13]. Patients
with these more serious mutations are more likely to produce a greater
immune response than is seen in patients with milder mutations. For
example, analyses of immunogenicity data from a study of idursulfase
ERT in children 16 months to 7.5 years of age, indicated a clear associa-
tion between the most severe genotype (complete deletion/large rear-
rangements) for MPS II and higher seroconversion rates and risk for
IRAEs [12]. Likewise in Pompe disease, patients with less endogenous
or functioning human acid α-glucosidase (cross-reactive immunologic
material-negative: associated with nonsense genotypes and more se-
vere disease) have been shown to have greater α-glucosidase antibody
titers compared to those with more benign splice site or frameshift α-
glucosidase mutations [14].
Four patients tested positive for idursulfase-specific IgM; however
since IgM is typically released both early and transiently during the
6 R. Giugliani et al. / Molecular Genetics and Metabolism Reports 12 (2017) 2–7course of an immune response [15], andnopatientwas treatment naïve,
IgM levels are less relevant when considering reactions to long-term
treatments.
The relationship between antibody status and pharmacodynamics
was analyzed by measuring uGAG levels over the duration of the
study. We found that Ab− and NAb− patients had lower baseline
uGAG levels at study entry than those who were Ab+ and NAb+, and
that this difference was maintained over the 2 year study period. Since
no pretreatment data are available for this study, no assessments
could be made regarding whether the observed higher baseline uGAG
levels in Ab+ patients were due to differences in therapeutic response
or to differences in pre-treatment levels. Previous studies have demon-
strated that uGAG levels in treatment-naive patients respond to treat-
ment with idursulfase [3,5,11]. The majority of the decrease occurs
quickly within the first few months of therapy, followed by a stable
long-term maintenance phase. Given that all patients in the study had
received treatment with idursulfase prior to enrollment, the largest
part of any treatment effect, would have most likely occurred before
study entry. Our data show that any previously attained pharmacody-
namic efficacy was maintained during this study.
There were nomeaningful clinical differences in the number or type
of AEs observed between patients with different antibody status. This
agrees with the phase 2/3 study where TEAEs and SAEs were statistical-
ly no more likely to occur in Ab+ patients than in Ab− patients. AEs
were experienced by virtually all patients (96%), a common finding in
ERT idursulfase studies [3,5,11].
In this observational study, which included both pediatric and adult
patients, age appeared to be an important predictor of immunogenicity
and risk. Among patients b12 years old, 59%were Ab+ at baseline com-
pared to only 33% of those ≥12 years. Patients whowere Ab+had a 2 to
3 times greater risk of experiencing IRAEs than those who were Ab−.
Age was an even greater factor with patients b12 years old having an
IRAE risk approximately 7 times that of older patients. Receiving
premedication for infusion is an indicator of prior IRAE history. In this
study, 7/17 (41%) of patients b12 years of age were pre-medicated at
week 1 while, none of the adolescent/adult patients (≥12 years) were
pre-medicated. Of the 9 patients reporting IRAEs during the study, 8
were pediatric patients versus only one adult patient. Younger patients
likely hadmore IRAEs before enrolling into the study, so it is not surpris-
ing to find younger age associated with Ab+ status and more study
IRAEs. Pano et al. demonstrated an association between themost severe
MPS II genotypes and risk for IRAEs in Hunter syndrome children on
idursulfase ERT [12]. As younger age was an indicator of more severe
disease, this possibly explains its association with IRAE rates (and anti-
body status). Similar findings were observed for NAb status [12]. Unfor-
tunately, the mutation status for patients in our study is not available.
IRAEs typically vary in frequency and intensity within the first
6 months of ERT, followed by a stable period with reduced need for
premedication [3,5]. For the present study, the 95% confidence intervals
around the RR for IRAEswere wide, and no statistically significant differ-
ences between antibody or age groups were observed. The pivotal study
and its extension, found that IRAEs were twice as likely to occur in pa-
tients who developed antibodies to idursulfase [4]. This study, where pa-
tients already had at least 6 months of treatment and 53% (14/26) of
patients received premedication to prevent IRAEs, makes comparisons
difficult with the pivotal study [3] where patients were treatment
naïve at baseline. Nine patients in the Ab+ group and 5 in the Ab−
group received premedication, whichmay have biased the observed dif-
ference between antibody groups in IRAE rates downward toward zero.
5. Conclusions
Long-term treatment with idursulfase (intravenous weekly infusion
at 0.5mg/kg)was found to be safe andwell tolerated for the 26 patients
who enrolled in the study and had been previously treated for at least
6 months prior to study entry, and for over 2 years of follow-up forthe 15 pediatric and adult MPS II patients who completed the study.
The interpretation of study results is limited by the fact that patients
were not treatment naive at study entry and their risk for IRAEs was
modified by use of premedication both before enrollment and/or during
the study. The immunogenicity profile, showing that approximately half
of the patients had at least one sample positive for antibodies, was sim-
ilar to that shown in previous studies. It was observed that Ab+ pa-
tients had higher uGAG levels than Ab− patients, and antibodies
developed more frequently in younger patients with more severe dis-
ease. Given the small sample size, a statistically significant effect of an-
tibody status on IRAE rates or changes in uGAG levels was not
demonstrated.
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